All Posts

Executive Summary- ADC clinical development Antibody–drug conjugates (ADCs) have achieved major advances at the scientific and engineering levels, yet clinical success remains highly variable. Many ADCs: show strong performance in preclinical models demonstrate early responses in Phase I trials ultimately fail in Phase II or Phase III studies This indicates that the challenge is not solely molecular design, but rather: ADC clinical development strategy Successful ADC programs

In Vivo CAR-T Autoimmune Therapy: Reprogramming the Immune System In Situ Introduction CAR-T therapy has already transformed hematologic oncology. Yet its expansion into autoimmune disease has been limited by cost, manufacturing complexity, and scalability challenges. A new paradigm is emerging: in vivo CAR-T autoimmune therapy . Instead of extracting T cells, engineering them ex vivo, and reinfusing them weeks later, in vivo approaches program immune cells directly inside th

Executive Summary Over the past decade, antibody–drug conjugates (ADCs) have become one of the most important therapeutic platforms in oncology drug development. Several ADCs have achieved major clinical success, particularly in breast cancer, hematologic malignancies, and emerging solid tumor indications. However, early generations of ADCs were still constrained by important limitations, including: reliance on a single payload mechanism dependence on a single tumor antigen

Introduction Following the success of COVID-19 vaccines, mRNA technology has rapidly emerged as one of the most important platforms in modern biotechnology . By enabling human cells to temporarily produce therapeutic proteins, mRNA therapeutics are being explored across a wide range of medical applications, including: Vaccines Cancer immunotherapy Protein replacement therapies Gene editing (CRISPR delivery) However, mRNA molecules are inherently fragile. Without protection,

Article Positioning This is Series (V) in the ADC deep-dive. In previous articles, we explored: The system-level design of antibody–drug conjugates Linker and conjugation engineering ADC target selection Clinical translation and platform strategy This article focuses on a critical reality: Even clinically successful ADCs eventually face ADC resistance . Understanding the mechanisms of ADC resistance is essential not only for biology, but for long-term product strategy. Execut

Introduction This is the fourth article in the ADC series. If previous articles discussed: The integrated system of antibody–drug conjugates (Series I) The evolution of ADC generations (Series II) Linker and conjugation as the engineering core (Series III) This article moves upstream to a more fundamental question: ADC target selection — which antigens are biologically suitable for ADC development? This article is written for readers without prior ADC experience who want to u

Introduction Why Has the LNP Field Long Lacked a “PDB-Level” Database? If you have worked directly on lipid nanoparticle (LNP) design for mRNA, siRNA, or CRISPR delivery, this situation may feel familiar: Extensive LNP screening has been performed across the field, yet much of the resulting data never truly accumulates into shared knowledge. The LNP field faces a structural challenge: large volumes of data exist, but they are highly fragmented and difficult to integrate. Diff

Introduction This is the third article in LuTra Studio’s ADC series, written for readers without a chemistry or ADC engineering background  who want to understand why many antibody–drug conjugate programs fail despite having strong targets and potent payloads . This article focuses on ADC linker design and conjugation strategy —two elements often treated as technical details, but which frequently become structural failure points  in clinical development and manufacturing scal